National Pension Service Grows Position in Zoetis Inc. $ZTS

National Pension Service lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 9.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 839,875 shares of the company’s stock after purchasing an additional 73,785 shares during the quarter. National Pension Service’s holdings in Zoetis were worth $60,353,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Brighton Jones LLC grew its position in Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after buying an additional 2,978 shares during the period. Empowered Funds LLC boosted its stake in shares of Zoetis by 6.2% during the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after acquiring an additional 657 shares in the last quarter. Intech Investment Management LLC grew its position in shares of Zoetis by 17.2% during the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock valued at $1,374,000 after acquiring an additional 1,224 shares during the period. Sivia Capital Partners LLC raised its holdings in Zoetis by 73.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after purchasing an additional 1,422 shares during the period. Finally, Glenview Trust co boosted its position in Zoetis by 11.8% during the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock worth $745,000 after purchasing an additional 506 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Trading Up 0.3%

Shares of NYSE ZTS opened at $73.05 on Friday. The stock has a fifty day simple moving average of $75.56 and a 200-day simple moving average of $91.97. Zoetis Inc. has a twelve month low of $71.00 and a twelve month high of $150.05. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The stock has a market capitalization of $30.19 billion, a PE ratio of 12.03, a PEG ratio of 1.70 and a beta of 0.73.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. The company had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business’s revenue for the quarter was down .2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, equities analysts forecast that Zoetis Inc. will post 6.2 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ZTS. UBS Group cut their price objective on Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a research report on Friday, August 7th. TD Cowen reduced their price objective on shares of Zoetis from $104.00 to $94.00 and set a “buy” rating for the company in a research report on Tuesday, August 25th. JPMorgan Chase & Co. cut their target price on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, August 7th. Stifel Nicolaus lowered their price objective on Zoetis from $85.00 to $80.00 and set a “hold” rating on the stock in a report on Thursday, August 20th. Finally, HSBC reduced their target price on Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a report on Monday, July 6th. Eight equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $101.08.

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity.

The company’s product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services.